Sophiris Bio, Inc. (NASDAQ:SPHS) is set to issue its quarterly earnings data on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.
Shares of Sophiris Bio, Inc. (NASDAQ:SPHS) opened at 2.16 on Tuesday. The firm’s market cap is $65.04 million. The firm’s 50-day moving average price is $2.26 and its 200-day moving average price is $2.24. Sophiris Bio, Inc. has a one year low of $1.80 and a one year high of $3.24.
An institutional investor recently raised its position in Sophiris Bio stock. Vanguard Group Inc. boosted its holdings in Sophiris Bio, Inc. (NASDAQ:SPHS) by 1.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 731,437 shares of the biopharmaceutical company’s stock after buying an additional 7,600 shares during the quarter. Vanguard Group Inc. owned 2.43% of Sophiris Bio worth $1,609,000 as of its most recent SEC filing. 5.78% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently commented on SPHS. Maxim Group set a $6.00 target price on Sophiris Bio and gave the stock a “buy” rating in a report on Monday, October 2nd. HC Wainwright set a $6.00 target price on Sophiris Bio and gave the stock a “buy” rating in a report on Friday, August 11th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $6.60.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
What are top analysts saying about Sophiris Bio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sophiris Bio Inc. and related companies.